STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or	1
		the abstract	
		(b) Provide in the abstract an informative and balanced summary of what	1
		was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3
Setting	5	Describe the setting, locations, and relevant dates, including periods of	3-4
	J	recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and	NA
	O	methods of selection of participants. Describe methods of follow-up	1111
		Case-control study—Give the eligibility criteria, and the sources and	
		methods of case ascertainment and control selection. Give the rationale	
		for the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and	
		methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and	NA
		number of exposed and unexposed	INA
		Case-control study—For matched studies, give matching criteria and the	
		number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders,	3-5
	·	and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/	8*	For each variable of interest, give sources of data and details of methods	
measurement		of assessment (measurement). Describe comparability of assessment	
		methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If	4-5
Zaminami ve variables	11	applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	4-5
	12	confounding	
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) Cohort study—If applicable, explain how loss to follow-up was	NA
		addressed	1111
		Case-control study—If applicable, explain how matching of cases and	
		controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking	
		account of sampling strategy	
			NA
		(\underline{e}) Describe any sensitivity analyses	INA

esn	ITG

13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	NA	
	eligible, examined for eligibility, confirmed eligible, included in the study,		
	completing follow-up, and analysed		
	(b) Give reasons for non-participation at each stage	NA	
	(c) Consider use of a flow diagram	NA	
14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and	3-4	
	information on exposures and potential confounders		
	(b) Indicate number of participants with missing data for each variable of interest	NA	
	(c) Cohort study—Summarise follow-up time (eg, average and total amount)	NA	
Outcome data 15*	Cohort study—Report numbers of outcome events or summary measures over time	NA	
	Case-control study—Report numbers in each exposure category, or summary		
	measures of exposure		
	Cross-sectional study—Report numbers of outcome events or summary measures	5-9	
Main results 16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and	NA	
	their precision (eg, 95% confidence interval). Make clear which confounders were		
	adjusted for and why they were included		
	(b) Report category boundaries when continuous variables were categorized		
	(c) If relevant, consider translating estimates of relative risk into absolute risk for a	NA	
	meaningful time period		
17	Report other analyses done—eg analyses of subgroups and interactions, and		
	sensitivity analyses		
18	Summarise key results with reference to study objectives	9-10	
Limitations 19	Discuss limitations of the study, taking into account sources of potential bias or	12-	
	imprecision. Discuss both direction and magnitude of any potential bias	13	
Interpretation 20	Give a cautious overall interpretation of results considering objectives, limitations,	10-	
	multiplicity of analyses, results from similar studies, and other relevant evidence	12	
21	Discuss the generalisability (external validity) of the study results	12	
on			
22	Give the source of funding and the role of the funders for the present study and, if	13	
	14* 15* 16 17 18 19 20 21	eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total amount) 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 18 Summarise key results with reference to study objectives 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias or imprecision. Discuss both direction and magnitude of any potential bias 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 21 Discuss the generalisability (external validity) of the study results	

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.